Program

Preliminary Program. Subject to Changes & Updates.

TimeSession
08:30Welcome Coffee
09:15Opening Remarks – Organizers
09:20Keynote I: Mathias Vormehr – Senior Director Cancer Vaccines – BioNTech – “mRNA vaccines for the treatment of cancer”
10:00Company Presentations I:
Covadonga Pañeda
– Altamira Therapeutics- “TBA”
Irma
Ochigava
– CapCoBio – “TBA”
Constance Ciaudo Beyer – DeepLife – “TBA”
Dominik Witzigmann – NannoVation Therapeutics – “TBA”
TBA – Sylentis – “TBA”
More to be announced
10:30Coffee Break
11:00Short Talk on Rare Disease Clinical Projects:
Matias Wagner – Institute of Human Genetics, Klinikum rechts der Isar, Technical University Munich – “TBA”
11:10Panel I – Medical Development:
Marc Abramowicz – Professor & Head, Genetic Medicine, University Hospital Geneva
Jasmin Barman-Aksözen – Triemli Hospital & University of Zurich
Matias Wagner – Institute of Human Genetics, Klinikum rechts der Isar, Technical University Munich
Annemieke Aartsma-Rus – Professor of Human Genetics – University of Leiden
11:40Poster Flash Talks
12:00Lunch & Poster Session & Networking & Sponsor Presentations
14:00Keynote II: Annemieke Aartsma-Rus – Professor of Human Genetics – University of Leiden – “From Duchenne exon skipping to N=1 treatment: Applying lessons learned for (very) rare disease patients”
14:40Young Scientists Career Talks:
Mateusz Mendel
– Senior Scientist Lead Discovery – Roche
15:00Academic Talks
Johannes Häberle – University Children’s Hospital Zurich & University of Zurich – “TBA”
Rory Johnson – UC Dublin & University of Bern – “TBA”
Deborah Stroka – Department for BioMedical Research, University of Bern – “TBA”
15:40Coffee Break
16:10
Company Presentations II
TBA – Roche – “TBA”
Troels Koch – MiNA Therapeutics – “TBA”
17:00Panel II – Patients, Society & RNA Medicine
Panelists TBA
17:30Concluding Remarks – Organizers
17:35Apéro